CVS Caremark Corp (CVS.N)
57.59USD
1 Jul 2013
$0.41 (+0.72%)
$57.18
$57.56
$58.57
$57.44
1,173,410
1,460,106
$60.70
$43.65
CVS.N
About
Overall
| Beta: | 0.77 |
| Market Cap (Mil.): | $70,512.77 |
| Shares Outstanding (Mil.): | 1,224.39 |
| Dividend: | 0.22 |
| Yield (%): | 1.56 |
Financials
| CVS.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 17.89 | 18.16 | 37.16 |
| EPS (TTM): | 3.22 | -- | -- |
| ROI: | 7.70 | 9.92 | 64.31 |
| ROE: | 10.66 | 11.17 | 70.34 |
Medicare patients do better taking drugs on time - study
June 27 - Americans on Medicare prescription drug plans do a better job of taking their medicines on time compared to other insured patients, and if more people followed their lead, it could save billions of dollars in healthcare costs, a report by CVS Caremark Corp concluded.
Haniel denies in talks with CVS to sell Celesio stake
DUESSELDORF, Germany - Diversified holding company Franz Haniel & Cie said on Wednesday it was not in talks with U.S. drugstore chain CVS to sell majority control over German drug distributor Celesio .
UPDATE 1-Haniel denies in talks with CVS to sell Celesio stake
* CVS prepared to pay Celesio 2 bln eur for stake -magazine
Haniel says not in talks with CVS to sell Celesio stake
DUESSELDORF, Germany, June 19 - Diversified holding company Franz Haniel & Cie on Wednesday said it was not in talks with U.S. group CVS to sell its 50.01 percent stake in German drug distributor Celesio, denying an earlier press report.
CVS Caremark profit rises, helped by generics, flu season
- CVS Caremark Corp posted a higher than expected first-quarter profit on Wednesday, helped by more profitable generic drugs on the market and a severe cold and flu season that boosted sales at its drugstores.
UPDATE 2-CVS Caremark profit rises, helped by generics, flu season
* CEO still confident can keep 60 pct of business won from Walgreen fight
BRIEF-CVS Caremark CEO says competiton for PBM contracts currently "competitive, yet rational"
May 1 - CVS Caremark Corp : * CEO says competiton for pbm contracts currently "competitive, yet rational" * CFO sees FY net revenue growth 1.75-3 percent * CFO sees FY net revenue growth 1.75-2.75 percent in pbm unit * CFO sees FY net revenue growth 2.25 percent-3.5 percent in retail pharmacy
BRIEF-CVS still "very confident" can keep 60 pct of scripts from Walgreen-Express Scripts spat
May 1 - CVS Caremark Corp : * Still "very confident" can keep at least 60 percent of scripts in 2013 gained
CVS Caremark posts higher profit, helped by flu season, generics
NEW YORK, May 1 - CVS Caremark Corp posted higher quarterly profit on Wednesday, as a more severe cold and flu season boosted sales and more new generic drugs hit the market.
CVS Caremark gets contract to serve 1.1 million CareFirst members
- CVS Caremark Corp is set to provide pharmacy benefit and other services for 1.1 million CareFirst BlueCross BlueShield members starting next year, a deal that could represent about $1 billion in annual spending on medications and boost CVS' profit by a penny per share, an industry analyst said.
Competitors
| Price | Change | |
|---|---|---|
| Medco Health Solutions Inc. (MHS.N) | -- | -- |
| UnitedHealth Group Inc. (UNH.N) | $65.63 | +0.15 |
| CIGNA Corporation (CI.N) | $72.81 | +0.32 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (CVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
